Comparison · NCT00103844-fa17c815
Dasatinib vs Imatinib: CHR After Crossover
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dasatinib vs Imatinib: CHR After Crossover. Trial comparisons, record NCT00103844-fa17c815. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00103844-fa17c815
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.949 | 0.831 | 0.986 | wilson | |
| Risk in group 2 | 0.65 | 0.433 | 0.819 | wilson | |
| Risk difference, group 1 minus group 2 | 0.299 | 0.093 | 0.519 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.46 | 1.05 | 2.03 | log | |
| Odds ratio, group 1 over group 2 | 9.96 | 1.83 | 54.2 | log | |
| Number needed to treat, for one more participant with the outcome on Dasatinib than on Imatinib | 3.35 | 1.93 | 10.8 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dasatinib | Dasatinib 70 mg twice a day (BID) | 37 | 39 | OG000 |
| Group 2 | Imatinib | Imatinib 400 mg BID | 13 | 20 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- CHR After Crossover
- Description
Participants achieving CHR after crossover. CHR=all of the following criteria: white blood cell count ≤ institutional upper limit of normal; platelets \< 450,000/mm³; no blasts or promyelocytes in peripheral blood; \< 5% myelocytes plus metamyelocytes in peripheral blood; peripheral blood basophils ≤ 20%; no extramedullary involvement. Confirmed CHR is defined as CHR maintained at least 4 weeks after first documented at ≥ Day 14. Failure to maintain criteria of CHR was defined by 2 or more consecutive records of non-response.
- Time frame
- Weekly for 12 weeks, then after every 12 week period out to 2 years; restricted to postcrossover measurements.
- Population
- Participants evaluable for response after crossover
Source ClinicalTrials.gov
Trial
- Title
- Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
- NCT number
- NCT00103844
- Phases
- PHASE2
- Conditions
- Chronic Myeloid Leukemia, Philadelphia-Positive Myeloid Leukemia
- Interventions
- Dasatinib, Imatinib
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2010-01-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00103844?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00103844-fa17c815